In fact, mitogen-activated protein kinase (MAPK) signaling is activated in more than 80% and phosphatidylinositiol-3-kinase (PI3K) signaling is activated in 50–70% of AML patient samples, suggesting a key role for these Ras effector pathways in AML maintenance [4, 5]. The gene discussed is WNK2; the disease is acute myeloid leukemia.